Oppenheimer lowered the firm’s price target on Alumis to $25 from $26 and keeps an Outperform rating on the shares following quarterly results and business update. This follows Tuesday’s news that shareholders of both Alumis (ALMS) and Acelyrin (SLRN) had approved the merger of the companies with the transaction expected to close in Q2, the firm notes.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALMS:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue